Role of PTK-7 in Acute Myeloid Leukemias

Role of PTK-7 in Acute Myeloid Leukemias: Impact of PTK7 Serum Marker and ex Vivo Studies to Decipher the Role of PTK7

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02860793

Acronym

LAM-PTK7

Enrollment

Registered

2016-08-09

Start date

2014-01-31

Completion date

Unknown

Last updated

2016-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Keywords

PTK7, Acute Myeloid Leukemia

Brief summary

The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway. PTK7 is expressed in normal myeloid progenitors and CD34(+) CD38(-) bone marrow cells in humans. It is also expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation. In AML, PTK7 seems to convey promigratory and antiapoptotic signals into the cell and represents an independent prognosis factor of survival in patients treated with induction chemotherapy. This study aims at: * evaluating the impact of PTK7 expression on primary AML cells ex vivo * evaluating the diagnostic and prognostic value of a soluble form of PTK7

Interventions

OTHERBone marrow aspiration

OTHERBlood sampling

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age\> 18 years * AML at diagnosis, not previously treated * Treatment by induction chemotherapy * Signed informed consent * Affiliation to the French social security system

Exclusion criteria

* pregnant woman(or of childbearing potential) or breastfeeding woman * emergency * patients deprived of liberty or placed under the authority of a tutor

Design outcomes

Primary

Measure	Time frame
Soluble PTK7 measurement in the serum	12 years
Evaluation PTK7+ and PTK7- AML cells hematopoietic homing abilities in xenografted mice by in vivo bioluminescence imaging	1 day

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026